摘要
目的观察硼替佐米联合化疗治疗初发、复发多发性骨髓瘤患者的疗效及不良反应。方法 10例多发性骨髓瘤患者,其中初治7例,复发3例,使用BAD方案(硼替佐米1.3mg/m2,d1,d4,d8,d11;表阿霉素10mg,d1～4;地塞米松20～40mg,d1～4,d8～11)或BD方案(硼替佐米1.3mg/m2,d1,d4,d8,d11;地塞米松20～40mg,d1～2,d4～5,d8～9,d11～12);每例患者化疗2～4个疗程。结果 10例患者中完全缓解(CR)3例,接近完全缓解(nCR)3例,部分缓解(PR)2例,轻微反应(MR)1例,无变化(NC)1例,总体有效率为CR+nCR+PR:80.0%。主要不良反应包括周围神经炎,消化道反应,白细胞及血小板减少等。结论硼替佐米联合化疗治疗初治、复发多发性骨髓瘤患者疗效确切,不良反应轻微。
Objective To observe the efficacy and adverse reaction of bortezomib plus chemotherapy in treating newly-diagnosed and relapsed multiple myeloma（MM） patients. Methods Ten patients of multiple myeloma,7 newly- diagnosed patients and 3 relapsed patients, who used BAD regimen （bortezomib 1.3 mg/m2 on clays 1,4,8 and 11 ; epidoxorubi 10 mg per day on days 1 to 4;dexamethasone 20-40 mg on days 1-4,8-11） or BD regimen（bortezomib 1.3 mg/m2 on days 1,4,8 and ll;dexamethasone 20-40 mg on days 1-2,4-5,8-9 and 11-12） ;Each patient received 2 to 4 cycles in the therapy. Results Among 10 patients,3 patients had complete response（CR） ,3 had near complete response （nCR） ,2 had partial response（PR）,1 had minimal response（MR）,1 had no change（NC）,and the overall effective rate of CR ＋ nCR ＋ PR was 80.0%. The main adverse effects were peripheral neuropathy, gastrointestinal symptoms, leucopenia, thrombocytopenia, etc. Conclusion Bortezomib plus chemotherapy was well tolerated and effective in treating either newly-diagnosed or relapsed MM patients with slight adverse effects.
出处
《临床荟萃》
CAS
2012年第24期2136-2137,2141,共3页
Clinical Focus
关键词
多发性骨髓瘤
抗肿瘤联合化疗方案
硼替佐米
multiple myeloma
antineoplastic combined chemotheraphy protocols
bortezomib
